NicOx has announced the private placement of 3.5 million new ordinary shares priced at €7.5 ($8.85) each to raise €26.25m ($30.97m) in total.

Based in France, NicOx is a pharmaceutical company focused on the development of treatments for ophthalmic conditions. The company plans to use the funds to progress the development of its products and for general corporate purposes.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

US-based biopharmaceutical company FibroGen has announced a public offering of eight million common stock shares priced at $40.75 a share to raise $300m in total.

The company plans to use the funds towards product development, clinical programmes and commercialisation activities.

“US-based biopharmaceutical company FibroGen has announced a public offering of eight million common stock shares priced at $40.75 a share to raise $300m in total.”

Omeros has announced a public offering of three million common stock shares priced at $22.75 a share to raise $68.25m.

The US-based biopharmaceutical company plans to use the funds towards general corporate purposes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Apellis Pharmaceuticals has raised $60m in a Series E funding round led by Sectoral Asset Management.

Based in the US, the clinical-stage biopharmaceutical company plans to use the funds to progress the development of its APL-2 drug.